Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. März 2024 02:00 ET | Quelle: Verona Pharma plc

Andrew Fisher Joins Verona Pharma as General Counsel

Verona Pharma announces Mr. Andrew Fisher has today joined the Company as General Counsel, and member of the Executive Management Team.
01. Februar 2024 02:00 ET | Quelle: Verona Pharma plc

Michael Austwick Joins Verona Pharma as Non-Executive Director

LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director. ...
03. Oktober 2023 02:00 ET | Quelle: Verona Pharma plc

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023

PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 LONDON...
11. September 2023 02:00 ET | Quelle: Verona Pharma plc

Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD

PDUFA Target Action Date of June 26, 2024 Ensifentrine, if approved, is expected to be the first novel mechanism available for the maintenance treatment of COPD in more than a decade LONDON and...
07. Januar 2020 12:30 ET | Quelle: Franciosi Consulting Ltd.

Luigi Franciosi to Advise on New Asthma & COPD Drug Development Programs for Vicenna Pharmaceuticals Inc.

VANCOUVER, British Columbia, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Franciosi Consulting Ltd. (“FCL”) is pleased to announce that its President and CEO, Dr. Luigi Franciosi, has been retained as a...